Meet Your ETF AI Analyst
- Discover how TipRanks' ETF AI Analyst can help you make smarter investment decisions
- Explore ETFs TipRanks' users love and see what insights the ETF AI Analyst reveals about the ones you follow.
Lucid Diagnostics ( (LUCD) ) has issued an update.
Lucid Diagnostics reported its third-quarter 2025 financial results, highlighting the processing of 2,841 EsoGuard tests and revenue of $1.2 million. The company ended the quarter with over $47 million in cash, extending its financial runway through 2026. A significant development was the unanimous expert consensus at the Multi-Jurisdictional Contractor Advisory Committee meeting supporting Medicare coverage for EsoGuard, marking a crucial step towards securing transformative Medicare coverage. The company also strengthened its market access team and announced upcoming initiatives, including a summit focused on cancer prevention in the fire service.
The most recent analyst rating on (LUCD) stock is a Hold with a $1.00 price target. To see the full list of analyst forecasts on Lucid Diagnostics stock, see the LUCD Stock Forecast page.
Spark’s Take on LUCD Stock
According to Spark, TipRanks’ AI Analyst, LUCD is a Neutral.
Lucid Diagnostics shows promising revenue growth and strategic partnerships, but significant challenges remain. The company’s high leverage and negative cash flows present financial risks, and the stock’s technical indicators suggest a bearish trend. The earnings call provided a cautiously optimistic outlook, focusing on Medicare coverage as a critical milestone. Overall, the stock’s score reflects the balance of these factors, with financial performance being the most significant concern.
To see Spark’s full report on LUCD stock, click here.
More about Lucid Diagnostics
Lucid Diagnostics Inc. is a commercial-stage medical diagnostics company focused on cancer prevention, specifically through its EsoGuard Esophageal DNA Test. As a subsidiary of PAVmed Inc., Lucid operates in the healthcare industry with a market focus on early cancer detection and prevention.
Average Trading Volume: 1,182,869
Technical Sentiment Signal: Sell
Current Market Cap: $144.1M
See more data about LUCD stock on TipRanks’ Stock Analysis page.